DePuy develops and markets products under the Codman, DePuy Mitek, DePuy Orthopaedics and DePuy Spine brands. The company operates as a comprehensive orthopedic and neurosurgery platform serving physicians, hospitals, surgeons, and healthcare systems across domestic and international markets. The business is valued at more than $9 billion, positioning it as a significant player in global orthopedic surgery and spine solutions.
Cyborg Score Rationale
DePuy Synthes operates as a diversified orthopedic medical device leader with strong global market presence, established product portfolios across trauma, joint reconstruction, and spine. However, ongoing litigation liabilities and the announced J&J spinoff within 18-24 months introduce operational and strategic uncertainty that tempers the rating.
Top Insights
Planned spinoff from Johnson & Johnson (October 2025) will transform DePuy Synthes into an independent public company within 18-24 months, reshaping capital structure and strategic autonomy
Portfolio spans seven product categories (trauma, joint reconstruction, spine, sports medicine, neuro, cranio-maxillofacial, power tools) with established brands and global distribution networks
Recent strategic partnerships and acquisitions (May 2026 CGBIO NOVOSys distribution agreement and MinMaxMedical tracking technology acquisition) signal active M&A and innovation momentum
Significant litigation exposure from ASR XL hip implant legacy issues (11,000+ plaintiffs) with ongoing financial settlement obligations impacting profitability
Named Competitors
Globus Medical — Orthopedic and neurosurgery medical devices
Bioventus — Orthopedic regenerative medical devices
ExacTech — Orthopedic implants and joint reconstruction
Stryker Orthopedics — Medical technology including orthopedic devices
Zimmer Biomet — Orthopedic and musculoskeletal healthcare solutions
Recent Developments
(May 2026) Entered exclusive U.S., Canada and Australia distribution agreement for CGBIO's NOVOSIS technology
(May 2026) Announced agreement to acquire miniature radiofrequency tracking technology from MinMaxMedical
(October 2025) Johnson & Johnson announced planned divestiture of DePuy Synthes over 18-24 months
(December 2025) $20 million damages verdict issued related to patent assignment case
Open the full interactive DePuy Synthes report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.